{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T17:31:31Z","timestamp":1770831091614,"version":"3.50.1"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2024,1,3]],"date-time":"2024-01-03T00:00:00Z","timestamp":1704240000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["F32AI169905"],"award-info":[{"award-number":["F32AI169905"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,5,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The field of infectious diseases saw numerous exciting advances in 2023. Trials of new antibiotics and treatment regimens sought to address rising rates of antimicrobial resistance. Other studies focused on the most appropriate use of currently available treatments, balancing the dual goals of providing effective treatment and impactful antimicrobial stewardship. Improvements in disease prevention were made through trials of both new vaccines and new chemoprophylaxis approaches. Concerning trends this year included increasing rates of invasive group A streptococcal infections, medical tourism-associated cases of fungal meningitis, and the return of locally acquired malaria to the United States. This review covers some of these notable trials and clinical developments in infectious diseases in the past year.<\/jats:p>","DOI":"10.1093\/cid\/ciad789","type":"journal-article","created":{"date-parts":[[2024,1,3]],"date-time":"2024-01-03T15:59:12Z","timestamp":1704297552000},"page":"1170-1174","source":"Crossref","is-referenced-by-count":4,"title":["What's Hot This Year in Infectious Diseases Clinical Science"],"prefix":"10.1093","volume":"78","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5788-1481","authenticated-orcid":false,"given":"Jeffrey A","family":"Freiberg","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Vanderbilt University Medical Center , Nashville, Tennessee , USA"},{"name":"Vanderbilt Institute for Infection, Immunology, and Inflammation, Vanderbilt University Medical Center , Nashville, Tennessee , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4664-6328","authenticated-orcid":false,"given":"Patty W","family":"Wright","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Vanderbilt University Medical Center , Nashville, Tennessee , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,1,3]]},"reference":[{"key":"2024051423580508300_ciad789-B1","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S0140-6736(21)02724-0","article-title":"Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis","volume":"399","author":"Antimicrobial Resistance Collaborators","year":"2022","journal-title":"Lancet"},{"key":"2024051423580508300_ciad789-B2","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/S1473-3099(17)30753-3","article-title":"Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis","volume":"18","author":"Tacconelli","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"2024051423580508300_ciad789-B3","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1016\/S1473-3099(23)00184-6","article-title":"Efficacy and safety of sulbactam-durlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii-calcoaceticus complex: a multicentre, randomised, active-controlled, phase 3, non-inferiority clinical trial (ATTACK)","volume":"23","author":"Kaye","year":"2023","journal-title":"Lancet Infect Dis"},{"key":"2024051423580508300_ciad789-B4","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1093\/cid\/ciac738","article-title":"Sulopenem or ciprofloxacin for the treatment of uncomplicated urinary tract infections in women: a phase 3, randomized trial","volume":"76","author":"Dunne","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2024051423580508300_ciad789-B5","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1093\/cid\/ciac704","article-title":"Sulopenem for the treatment of complicated urinary tract infections including pyelonephritis: a phase 3, randomized trial","volume":"76","author":"Dunne","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2024051423580508300_ciad789-B6","author":"Iterum Therapeutics, International Limited"},{"key":"2024051423580508300_ciad789-B7","article-title":"Colistin monotherapy versus combination therapy for carbapenem-resistant organisms","volume":"2","author":"Kaye","year":"2022","journal-title":"NEJM Evid"},{"key":"2024051423580508300_ciad789-B8","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1001\/jama.2023.10598","article-title":"Continuous vs intermittent meropenem administration in critically ill patients with sepsis: the MERCY randomized clinical trial","volume":"330","author":"Monti","year":"2023","journal-title":"JAMA"},{"key":"2024051423580508300_ciad789-B9","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/S1473-3099(17)30615-1","article-title":"Prolonged versus short-term intravenous infusion of antipseudomonal \u03b2-lactams for patients with sepsis: a systematic review and meta-analysis of randomised trials","volume":"18","author":"Vardakas","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"2024051423580508300_ciad789-B10","doi-asserted-by":"crossref","first-page":"993","DOI":"10.17219\/acem\/121934","article-title":"Clinical outcomes of continuous vs intermittent meropenem infusion for the treatment of sepsis: a systematic review and meta-analysis","volume":"29","author":"Chen","year":"2020","journal-title":"Adv Clin Exp Med"},{"key":"2024051423580508300_ciad789-B11","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1164\/rccm.201505-0857OC","article-title":"A multicenter randomized trial of continuous versus intermittent \u03b2-lactam infusion in severe sepsis","volume":"192","author":"Dulhunty","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"2024051423580508300_ciad789-B12","first-page":"63","article-title":"A protocol for a phase 3 multicentre randomised controlled trial of continuous versus intermittent \u03b2-lactam antibiotic infusion in critically ill patients with sepsis: BLING III","volume":"21","author":"Lipman","year":"2019","journal-title":"Crit Care Resusc"},{"key":"2024051423580508300_ciad789-B13","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1056\/NEJMoa2117166","article-title":"A 24-week, all-oral regimen for rifampin-resistant tuberculosis","volume":"387","author":"Nyang\u2019wa","year":"2022","journal-title":"N Engl J Med"},{"key":"2024051423580508300_ciad789-B14","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1093\/cid\/ciad070","article-title":"Antimicrobial for 7 or 14 days for febrile urinary tract infection in men: a multicenter noninferiority double-blind, placebo-controlled, randomized clinical trial","volume":"76","author":"Lafaurie","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2024051423580508300_ciad789-B15","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1001\/jama.2021.9899","article-title":"Effect of 7 vs 14 days of antibiotic therapy on resolution of symptoms among afebrile men with urinary tract infection: a randomized clinical trial","volume":"326","author":"Drekonja","year":"2021","journal-title":"JAMA"},{"key":"2024051423580508300_ciad789-B16","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1001\/jama.2023.5728","article-title":"Piperacillin-tazobactam compared with cefoxitin as antimicrobial prophylaxis for pancreatoduodenectomy: a randomized clinical trial","volume":"329","author":"D\u2019Angelica","year":"2023","journal-title":"JAMA"},{"key":"2024051423580508300_ciad789-B17","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1093\/cid\/cix801","article-title":"Corticosteroids in patients hospitalized with community-acquired pneumonia: systematic review and individual patient data metaanalysis","volume":"66","author":"Briel","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2024051423580508300_ciad789-B18","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1056\/NEJMoa2215145","article-title":"Hydrocortisone in severe community-acquired pneumonia","volume":"388","author":"Dequin","year":"2023","journal-title":"N Engl J Med"},{"key":"2024051423580508300_ciad789-B19","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1001\/jama.2023.10854","article-title":"Identifying children likely to benefit from antibiotics for acute sinusitis: a randomized clinical trial","volume":"330","author":"Shaikh","year":"2023","journal-title":"JAMA"},{"key":"2024051423580508300_ciad789-B20","author":"Pfizer"},{"key":"2024051423580508300_ciad789-B21","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1056\/NEJMoa2118542","article-title":"Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19","volume":"386","author":"Hammond","year":"2022","journal-title":"N Engl J Med"},{"key":"2024051423580508300_ciad789-B22","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1001\/jama.1993.03510200062033","article-title":"Clinical experience with penicillin skin testing in a large inner-city STD clinic","volume":"270","author":"Gadde","year":"1993","journal-title":"JAMA"},{"key":"2024051423580508300_ciad789-B23","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1001\/jamainternmed.2023.2986","article-title":"Efficacy of a clinical decision rule to enable direct oral challenge in patients with low-risk penicillin allergy: the PALACE randomized clinical trial","volume":"183","author":"Copaescu","year":"2023","journal-title":"JAMA Intern Med"},{"key":"2024051423580508300_ciad789-B24","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1001\/jamainternmed.2020.0403","article-title":"Development and validation of a penicillin allergy clinical decision rule","volume":"180","author":"Trubiano","year":"2020","journal-title":"JAMA Intern Med"},{"key":"2024051423580508300_ciad789-B25","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1056\/NEJMoa2209604","article-title":"Respiratory syncytial virus prefusion F protein vaccine in older adults","volume":"388","author":"Papi","year":"2023","journal-title":"N Engl J Med"},{"key":"2024051423580508300_ciad789-B26","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1056\/NEJMoa2213836","article-title":"Efficacy and safety of a bivalent RSV prefusion F vaccine in older adults","volume":"388","author":"Walsh","year":"2023","journal-title":"N Engl J Med"},{"key":"2024051423580508300_ciad789-B27","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2216480","article-title":"Bivalent prefusion F vaccine in pregnancy to prevent RSV illness in infants","volume":"388","author":"Kampmann","year":"2023","journal-title":"N Engl J Med"},{"key":"2024051423580508300_ciad789-B28","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/ajt.12006","article-title":"CMV: prevention, diagnosis and therapy","volume":"13","author":"Kotton","year":"2013","journal-title":"Am J Transplant"},{"key":"2024051423580508300_ciad789-B29","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1001\/jama.2023.9106","article-title":"Letermovir vs valganciclovir for prophylaxis of cytomegalovirus in high-risk kidney transplant recipients: a randomized clinical trial","volume":"330","author":"Limaye","year":"2023","journal-title":"JAMA"},{"key":"2024051423580508300_ciad789-B30","first-page":"351","article-title":"Increases in group A streptococcal infections in the pediatric population in Houston, TX, 2022","volume":"77","author":"Aboulhosn","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2024051423580508300_ciad789-B31","author":"European Centre for Disease Prevention and Control"},{"key":"2024051423580508300_ciad789-B32","doi-asserted-by":"crossref","first-page":"265","DOI":"10.15585\/mmwr.mm7210a4","article-title":"Notes from the field: increase in pediatric invasive group A Streptococcus infections\u2014Colorado and Minnesota, October-December 2022","volume":"72","author":"Barnes","year":"2023","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2024051423580508300_ciad789-B33","doi-asserted-by":"crossref","first-page":"2300291","DOI":"10.2807\/1560-7917.ES.2023.28.26.2300291","article-title":"Increase in invasive group A streptococcal infections and emergence of novel, rapidly expanding sub-lineage of the virulent Streptococcus pyogenes M1 clone, Denmark, 2023","volume":"28","author":"Johannesen","year":"2023","journal-title":"Eurosurveillance"},{"key":"2024051423580508300_ciad789-B34","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.3201\/eid2910.230675","article-title":"Expansion of invasive group A Streptococcus M1UK lineage in active bacterial core surveillance, United States, 2019\u20132021","volume":"29","author":"Li","year":"2023","journal-title":"Emerg Infect Dis"},{"key":"2024051423580508300_ciad789-B35","doi-asserted-by":"crossref","first-page":"taaa210","DOI":"10.1093\/jtm\/taaa210","article-title":"Infectious complications related to medical tourism","volume":"28","author":"Pavli","year":"2021","journal-title":"J Travel Med"},{"key":"2024051423580508300_ciad789-B36","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciad570","article-title":"Update on outbreak of fungal meningitis among US residents who received epidural anesthesia at two clinics in Matamoros, Mexico","author":"Smith","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2024051423580508300_ciad789-B37","author":"Centers for Disease Control and Prevention"},{"key":"2024051423580508300_ciad789-B38","doi-asserted-by":"crossref","first-page":"3893","DOI":"10.1038\/s41598-023-28247-2","article-title":"Climate warming and increasing Vibrio vulnificus infections in North America","volume":"13","author":"Archer","year":"2023","journal-title":"Sci Rep"},{"key":"2024051423580508300_ciad789-B39","author":"Centers for Disease Control and Prevention"},{"key":"2024051423580508300_ciad789-B40","author":"Centers for Disease Control and Prevention"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciad789\/55566582\/ciad789.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/78\/5\/1170\/57638082\/ciad789.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/78\/5\/1170\/57638082\/ciad789.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,14]],"date-time":"2024-05-14T23:58:29Z","timestamp":1715731109000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/78\/5\/1170\/7505444"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,3]]},"references-count":40,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,1,3]]},"published-print":{"date-parts":[[2024,5,15]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciad789","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,5,15]]},"published":{"date-parts":[[2024,1,3]]}}}